NCT06010992

Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus

A Clinical Study Evaluating the Potential Benefit of Nitazoxanide in Patients With Type 2 Diabetes Mellitus

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Diabetes mellitus (DM) is a complex metabolic disorder characterized by hyperglycemia and abnormalities in carbohydrate, fat, and protein metabolism. Despite the advancement in anti-diabetic drug therapy, most patients fail to achieve optimal glycemic control. This highlights the need for more effective strategies to control type 2 diabetes mellitus. Nitazoxanide (NTZ), a broad-spectrum anti-infective drug with activity against various protozoa, helminthes, bacteria, and viruses, was identified as peroxisome proliferative activated receptor gamma (PPARγ) agonist using one dimensional drug profile matching. Additionally, it improved insulin sensitivity in insulin-resistant type 2 diabetic rats. Therefore, this study is designed to evaluate the efficacy of nitazoxanide as adjunctive therapy in patients with type 2 diabetes mellitus.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Nitazoxanide	Nitazoxanide oral capsules 500 mg twice daily

Timeline

• Start date: 2023-10-01
• Primary completion: 2024-10-01
• Completion: 2025-01-01
• First posted: 2023-08-25
• Last updated: 2023-08-25

Locations

2 sites across 1 country: Egypt